Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 11/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.43 |
| ▸ | GFRA3 | O60609 | 3/20 | 0.42 |
| ▸ | GNA15 | P30679 | 1/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | GFRA2 | O00451 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1746734 | 0.89 | FFAR1 (0.58) | FFAR1FFAR4GFRA3GNA15PTGER3 | |
| SCHEMBL1747248 | 0.88 | GRIN2B (0.44) | FFAR1TDP1PPARDGRIN2BGRIN1 | |
| SCHEMBL1744689 | 0.88 | FFAR1 (0.46) | FFAR1GFRA3RETPPARD | |
| SCHEMBL1744612 | 0.88 | FFAR1 (0.48) | FFAR1FFAR4GRIN2BGRIN1 | |
| SCHEMBL1745440 | 0.88 | GFRA3 (0.48) | FFAR1FFAR4GFRA3RETPPARD | |
| SCHEMBL1745404 | 0.86 | FFAR1 (0.47) | FFAR1PPARDGRIN2BGRIN1 | |
| SCHEMBL1744681 | 0.86 | FFAR1 (0.52) | FFAR1GFRA3GFRA2 | |
| SCHEMBL1744692 | 0.86 | FFAR1 (0.52) | FFAR1GFRA3GFRA2 | |
| SCHEMBL1745225 | 0.86 | FFAR1 (0.52) | FFAR1GFRA3GFRA2 | |
| SCHEMBL1745539 | 0.85 | FFAR1 (0.40) | FFAR1FFAR4TDP1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | FFAR1 33/4885FFAR4 44/4885GFRA3 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.